𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of esorubicin (4′-deozydoxorubicin) in advanced epithelial carcinoma of the ovary:A Gynecologic Oncology Group study

✍ Scribed by William P. McGuire; John A. Blessing; Michael L. Berman

Publisher
Springer US
Year
1989
Tongue
English
Weight
275 KB
Volume
7
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

✦ Synopsis

Twenty-six patients with advanced, measurable epithelial carcinoma of the ovary were treated with 76 courses of esorubicin at doses ranging from 20-30 mg/m2 every 3 weeks. All patients are evaluable for toxicity and response. All patients had received prior therapy including radiation therapy in 9, non-anthracycline chemotherapy in 25, and surgery in 25. All patients were GOG performance status 0, 1 or 2. Two partial responses were seen. Severe (grade 3 or 4) leukopenia, thrombocytopenia, and anemia were seen in 13, 1 and 4 patients, respectively. Moderate gastrointestinal toxicity was also noted. Alopecia and mucositis were rare. Phlebitis was not seen. Neither clinical congestive cardiomyopathy nor decrement in left ventricular ejection fraction was observed. We conclude that using this dose and schedule of esorubicin as second-line chemotherapy in ovarian epithelial neoplasms lacks significant activity and is associated with moderate toxicity.

📜 SIMILAR VOLUMES

Phase II evaluation of esorubicin (4′ de
Phase II evaluation of esorubicin (4′ deoxydoxorubicin) in pancreatic adenocarcinoma: A Southwest Oncology Group study
✍ Clarence B. Vaughn; Sydney E. Salmon; Thomas R. Fleming 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 335 KB

Esorubicin (4' deoxydoxorubicin) is a new analogue of the anthracycline, doxorubicin. This compound lacks the hydroxyl group at 4' position on the amino sugar of the anthracycline. Phase II study was designed to determine the clinical response rate and to define the qualitative and quantitative toxi

Phase II evaluation of mitoxantrone in a
Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: A Southwest Oncology Group study
✍ Sarah A. Taylor; Thomas Fleming; Daniel D. Hoff; Joseph D. McCracken; Ronald M. 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 242 KB

Patient with advanced adenocarcinoma of the pancreas and no prior chemotherapy were treated on a Phase II trial of mitoxantrone. Doses were adjusted for hepatic dysfunction as defined by bilirubin. Twenty-four patients with a bilirubin less than or equal to 1.5 mg% received mitoxantrone 12 mg/m2 i.v

Phase II study of esorubicin (4′ -deoxyd
Phase II study of esorubicin (4′ -deoxydoxorubicin) in locally advanced or metastatic head and neck carcinoma
✍ Sergio Frustaci; Giampietro Gasparini; Andrea Veronesi; Umberto Tirelli; Maria A 📂 Article 📅 1987 🏛 Springer US 🌐 English ⚖ 232 KB

Sixteen patients with locally advanced or metastatic head and neck cancer were treated with esorubicin (4'-deoxydoxorubicin) at a dose of 30-35 mg/m 2 i.v. every 3 weeks. One patient was lost to the follow up after one cycle, whereas in the 15 evaluable cases a total of 34 courses were administered